anagrelide
Also known as Agrylin®, BL-4162a, Xagrid®, Anagrelida, Anagrelidum
Anagrelide (Agrylin/Xagrid, Shire and Thromboreductin, AOP Orphan Pharmaceuticals AG) is a drug used for the treatment of essential thrombocytosis (also known as essential thrombocythemia), or overproduction of blood platelets. It has also been used in the treatment of chronic myeloid leukemia.
Chemical data
- Formula
- C10H7Cl2N3O
- Molecular weight
- 256.08 g/mol
- IUPAC name
- 6,7-dichloro-5,10-dihydro-3H-imidazo[2,1-b]quinazolin-2-one
- SMILES
- C1C2=C(C=CC(=C2Cl)Cl)NC3=NC(=O)CN31
- InChIKey
- OTBXOEAOVRKTNQ-UHFFFAOYSA-N
- XLogP
- 1.6
- Polar surface area
- 44.7 Ų
- H-bond donors
- 1
- H-bond acceptors
- 1
- Formal charge
- 0
via PubChem
Research
504 papersvia PubMed
Article
5 sectionsContents
- Medical uses
- Side-effects
- Mechanism of action
- Synthesis
- References
Anagrelide (Agrylin/Xagrid, Shire and Thromboreductin, AOP Orphan Pharmaceuticals AG) is a drug used for the treatment of essential thrombocytosis (also known as essential thrombocythemia), or overproduction of blood platelets. It has also been used in the treatment of chronic myeloid leukemia.
Anagrelide controlled release (GALE-401) is in phase III clinical trials by Galena Biopharma for the treatment of essential thrombocytosis.